Sign in
GDTC Stock Price, Chart, Stats & News
CytoMed Therapeutics Limited
Save
12.78M
Market cap
–
Current P/E
–
Forward P/E
GDTC chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 103.75% |
Operating margin | -715.04% |
Pretax margin | -914.95% |
Net margin | -913.41% |
Effective tax rate | – |
ROA | -50.97% |
ROE | -54.74% |
D/E | 0.07x |
Interest coverage ratio | -134.16x |
GDTC valuation
P/E | – |
P/S | 32.95x |
P/B | 2.16x |
P/CF | -5.07x |
P/FCF | -3.98x |
P/OCF | -5.07x |
PEG | 1.02x |
EV multiple | -5.45x |
About
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells.
Similar securities
Based on sector and market capitalization
Report issue